On November 16, 2022, MAPS submitted a revised protocol to the FDA in response to hold issues identified in the Agency’s Continued Partial Clinical Hold letters dated May 10 and December 27, 2021. MAPS has requested the FDA lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Read the cover letter here.